TEXCELL, announces the opening of its subsidiary in Japan to offer a viral security services solution to biotechs and pharmaceutical industries in Japan.
Bernard PLICHON, Chairman and CEO (chief executive officer) of the TEXCELL group: “After expanding its viral safety activities in the United States, with TEXCELL-NA (TEXCELL North America), in a new unit in Frederick (Maryland) in 2012, and in 2016 in Europe with the acquisition of VivoScience in Germany, TEXCELL is now expanding its commercial activity in Asia for customers, biotechs and pharmaceutical industries”.
TEXCELL has created a commercial subsidiary called TEXCELL JAPAN KK, based in Tokyo, active since October 2017.
Gene therapy and cell culture production are important strategic priorities in Japan, to which Texcell can contribute.
“The enthusiastic reception of our prospective customers in Japan shows the interest of the technical and commercial support that we are setting up, and validates Texcell’s strategy to be present on the three continents “.
In order to achieve its objectives in Japan, TEXCELL has trained a “Technical Sales Manager”, Matthieu Joguin, a Texcell employee for 3 years. He will be based in Osaka and will help with promotion.